HemoSonics-UVA Spinal Surgery
1 other identifier
observational
51
1 country
1
Brief Summary
This study compares the results of current standard coagulation measurement devices to the Quantra System, a new device, using small amount of extra blood obtained during routine blood draws in neurosurgery patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 13, 2015
CompletedFirst Posted
Study publicly available on registry
April 17, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2015
CompletedMay 11, 2016
May 1, 2016
4 months
April 13, 2015
May 10, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
assay inter-instrument variability
Demonstrate assay inter-instrument variability below 15%
1 day
Establish normal ranges
Establish normal ranges
1 day
Interventions
Blood specimen collection
Eligibility Criteria
Participants for this study will be recruited at the University of Virginia Medical Center. The subject population will be representative of the local racial and ethnic population.
You may qualify if:
- Subject is scheduled for major deformity correction spine surgery
- Subject is older than 18 years
- Subject is willing to participate and he/she has signed a consent form
You may not qualify if:
- Subject is unable to provide written informed consent
- Subject is incarcerated at the time of the study
- Subject is affected by any condition that, in the opinion of the surgical team, may pose additional risks
- Subjects with renal disease (defined as serum creatinine greater than 1.5 mg/dl)
- Subjects with history of active liver disease
- Subjects affected by Factor V Leiden mutation
- Subjects affected by von Willebrand disease
- Subjects with an history of thrombotic disease (more than one DVT)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Virginialead
- HemoSonics LLCcollaborator
Study Sites (1)
University of Virginia
Charlottesville, Virginia, 22908, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Bhiken Naik, MD
UVA Anethesiology Faculty
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- UVA Anesthesiology Faculty
Study Record Dates
First Submitted
April 13, 2015
First Posted
April 17, 2015
Study Start
April 1, 2015
Primary Completion
August 1, 2015
Study Completion
August 1, 2015
Last Updated
May 11, 2016
Record last verified: 2016-05
Data Sharing
- IPD Sharing
- Will not share